---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023871"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:21:42.027828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivos closes $7.5M private placement with Seneca; launches strategic alliance for sleep apnea treatment

## Summary
- Gross proceeds of $7.5M from sale of 3,220,266 shares/pre-funded warrants and 5-year warrants at $2.329/share to Seneca affiliate V-CO.
- Strategic alliance with Rebis Health (Colorado) to jointly offer CPAP and Vivos' oral appliances at two centers starting July 2024; revenue-sharing model.
- Seneca receives board observation rights and a management services fee of $37,500/quarter; cash participation in alliance net cash flow.
- Company intends to use proceeds for working capital; must file resale registration by July 25, 2024.
- Management expects new model to reduce cash burn, improve gross profit per case, and drive revenue growth.

## SEC filing metadata
- accession: 0001493152-24-023871
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224023871/0001493152-24-023871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224023871/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023871
- JSON: https://secwatch.observer/filing/0001493152-24-023871.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.